본문 바로가기
KERD
논문KCI 등재

Antiepileptic Drug Therapy for Status Epilepticus

노영주|김동욱|김근태|김재문|강경욱|서종근|조용원|이순태|김대영|양광익|변정익
대한신경과학회 (Korean Neurological Association)|2021.01|Journal of Clinical Neurology|제17권 제1호|pp. 11-19

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

seizurebenzodiazepinesstatus epilepticusantiepileptic drugsanestheticsdrug therapy.

초록

Status epilepticus (SE) is one of the most serious neurologic emergencies. SE is a condition that encompasses a broad range of semiologic subtypes and heterogeneous etiologies. The treatment of SE primarily involves the management of the underlying etiology and the use of antiepileptic drug therapy to rapidly terminate seizure activities. The Drug Committee of the Korean Epilepsy Society performed a review of existing guidelines and literature with the aim of providing practical recommendations for antiepileptic drug therapy. This article is one of a series of review articles by the Drug Committee and it summarizes staged antiepileptic drug therapy for SE. While evidence of good quality supports the use of benzodiazepines as the first-line treatment of SE, such evidence informing the administration of second- or third-line treatments is lacking; hence, the recommendations presented herein concerning the treatment of established and refractory SE are based on case series and expert opinions. The choice of antiepileptic drugs in each stage should consider the characteristics and circumstances of each patient, as well as their estimated benefit and risk to them. In tandem with the antiepileptic drug therapy, careful searching for and treatment of the underlying etiology are required.

Abstract

Status epilepticus (SE) is one of the most serious neurologic emergencies. SE is a condition that encompasses a broad range of semiologic subtypes and heterogeneous etiologies. The treatment of SE primarily involves the management of the underlying etiology and the use of antiepileptic drug therapy to rapidly terminate seizure activities. The Drug Committee of the Korean Epilepsy Society performed a review of existing guidelines and literature with the aim of providing practical recommendations for antiepileptic drug therapy. This article is one of a series of review articles by the Drug Committee and it summarizes staged antiepileptic drug therapy for SE. While evidence of good quality supports the use of benzodiazepines as the first-line treatment of SE, such evidence informing the administration of second- or third-line treatments is lacking; hence, the recommendations presented herein concerning the treatment of established and refractory SE are based on case series and expert opinions. The choice of antiepileptic drugs in each stage should consider the characteristics and circumstances of each patient, as well as their estimated benefit and risk to them. In tandem with the antiepileptic drug therapy, careful searching for and treatment of the underlying etiology are required.

참고문헌 (76)

  1. Trinka E, "A definition and classification of status epilepticus--report of the ILAE Task Force on classification of status epilepticus", Epilepsia, 56, pp.1515~1523 (2015)
  2. Kim D, "Seizure duration determined by subdural electrode recordings in adult patients with intractable focal epilepsy", J Epilepsy Res, 1, pp.57~64 (2011)
  3. Gastaut H, "Clinical and electroencephalographical classification of epileptic seizures", Epilepsia, 11, pp.102~113 (1970)
  4. Commission on Classification, "Proposal for revised clinical and electroencephalographic classification of epileptic seizures", Epilepsia, 22, pp.489~501 (1981)
  5. Shorvon SD, "Status epilepticus: its clinical features and treatment in children and adults", pp.21~33 (1994), Cambridge University Press
  6. Engel J Jr, "A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE Task Force on classification and terminology", Epilepsia, 42, pp.796~803 (2001)
  7. Rona S, "A semiological classification of status epilepticus", Epileptic Disord, 7, pp.5~12 (2005)
  8. Shorvon S, "The classification of status epilepticus", Epileptic Disord, 7, pp.1~3 (2005)
  9. "Am J Insanity", 1903, 291~306
  10. "Am J Insanity", 1904, 645~698
  11. "Am J Insanity", 1904, 81~108
  12. Shorvon S, "The treatment of super-refractory status epilepticus : a critical review of available therapies and a clinical treatment protocol", Brain, 134, pp.2802~2818 (2011)
  13. Trinka E, "Pharmacotherapy for status epilepticus", Drugs, 75, pp.1499~1521 (2015)
  14. Leppik IE, "Double-blind study of lorazepam and diazepam in status epilepticus", JAMA, 249, pp.1452~1454 (1983)
  15. Appleton R, "Lorazepam versus diazepam in the acute treatment of epileptic seizures and status epilepticus", Dev Med Child Neurol, 37, pp.682~688 (1995)
  16. Treiman DM, "A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group", N Engl J Med, 339, pp.792~798 (1998)
  17. Alldredge BK, "A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus", N Engl J Med, 345, pp.631~637 (2001)
  18. Sreenath TG, "Lorazepam versus diazepam-phenytoin combination in the treatment of convulsive status epilepticus in children : a randomized controlled trial", Eur J Paediatr Neurol, 14, pp.162~168 (2010)
  19. Silbergleit R, "Intramuscular versus intravenous therapy for prehospital status epilepticus", N Engl J Med, 366, pp.591~600 (2012)
  20. Chamberlain JM, "Lorazepam vs diazepam for pediatric status epilepticus : a randomized clinical trial", JAMA, 311, pp.1652~1660 (2014)
  21. Brophy GM, "Guidelines for the evaluation and management of status epilepticus", Neurocrit Care, 17, pp.3~23 (2012)
  22. Glauser T, "Evidence-based guideline : treatment of convulsive status epilepticus in children and adults : report of the guideline committee of the American Epilepsy Society", Epilepsy Curr, 16, pp.48~61 (2016)
  23. Minicucci F, "Management of status epilepticus in adults. Position paper of the Italian League against Epilepsy", Epilepsy Behav, 102, pp.106675~ (2020)
  24. Greenblatt DJ, "Kinetic and dynamic study of intravenous lorazepam : comparison with intravenous diazepam", J Pharmacol Exp Ther, 250, pp.134~140 (1989)
  25. Prasad M, "Anticonvulsant therapy for status epilepticus", Cochrane Database Syst Rev, 2014, pp.CD003723~ (2014)
  26. Shorvon S, "The drug treatment of status epilepticus in Europe: consensus document from a workshop at the first London Colloquium on Status Epilepticus", Epilepsia, 49, pp.1277~1285 (2008)
  27. Dundee JW, "Midazolam. A review of its pharmacological properties and therapeutic use", Drugs, 28, pp.519~543 (1984)
  28. Yasiry Z, "The relative effectiveness of five antiepileptic drugs in treatment of benzodiazepine-resistant convulsive status epilepticus: a meta-analysis of published studies", Seizure, 23, pp.167~174 (2014)
  29. Brigo F, "Intravenous antiepileptic drugs in adults with benzodiazepine-resistant convulsive status epilepticus : a systematic review and network meta-analysis", Epilepsy Behav, 101, pp.106466~ (2019)
  30. Cock HR, "Established status epilepticus treatment trial (ESETT)", Epilepsia, 52(Suppl 8), pp.50~52 (2011)
  31. Kapur J, "Randomized trial of three anticonvulsant medications for status epilepticus", N Engl J Med, 381, pp.2103~2113 (2019)
  32. Cranford RE, "Intravenous phenytoin : clinical and pharmacokinetic aspects", Neurology, 28, pp.874~880 (1978)
  33. Riviello JJ Jr, "Timing of maintenance phenytoin therapy after intravenous loading dose", Pediatr Neurol, 7, pp.262~265 (1991)
  34. O’Brien TJ, "Incidence and clinical consequence of the purple glove syndrome in patients receiving intravenous phenytoin", Neurology, 51, pp.1034~1039 (1998)
  35. Earnest MP, "Complications of intravenous phenytoin for acute treatment of seizures. Recommendations for usage", JAMA, 249, pp.762~765 (1983)
  36. Ramsay RE, "Intravenous administration of fosphenytoin : options for the management of seizures", Neurology, 46, pp.S17~ (1996)
  37. Limdi NA, "Safety of rapid intravenous loading of valproate", Epilepsia, 48, pp.478~483 (2007)
  38. Trinka E, "Efficacy and safety of intravenous valproate for status epilepticus : a systematic review", CNS Drugs, 28, pp.623~639 (2014)
  39. Bryant AE 3rd, "Valproic acid hepatic fatalities. III. U. S. experience since 1986", Neurology, 46, pp.465~469 (1996)
  40. Zelano J, "Levetiracetam as alternative stage two antiepileptic drug in status epilepticus : a systematic review", Seizure, 21, pp.233~236 (2012)
  41. Zheng F, "Levetiracetam for the treatment of status epilepticus", Expert Rev Neurother, 15, pp.1113~1121 (2015)
  42. Wasterlain CG, "The acute and chronic effects of the novel anticonvulsant lacosamide in an experimental model of status epilepticus", Epilepsy Res, 94, pp.10~17 (2011)
  43. Höfler J, "Lacosamide as a new treatment option in status epilepticus", Epilepsia, 54, pp.393~404 (2013)
  44. Strzelczyk A, "Lacosamide in status epilepticus : systematic review of current evidence", Epilepsia, 58, pp.933~950 (2017)
  45. Santamarina E, "Intravenous lacosamide(LCM)in status epilepticus(SE) : weight-adjusted dose and efficacy", Epilepsy Behav, 84, pp.93~98 (2018)
  46. Ramsay RE, "Safety & pK of IV loading dose of lacosamide in the ICU", Epilepsy Behav, 49, pp.340~342 (2015)
  47. Mayer SA, "Refractory status epilepticus : frequency, risk factors, and impact on outcome", Arch Neurol, 59, pp.205~210 (2002)
  48. Holtkamp M, "Predictors and prognosis of refractory status epilepticus treated in a neurological intensive care unit", J Neurol Neurosurg Psychiatry, 76, pp.534~539 (2005)
  49. Novy J, "Refractory status epilepticus : a prospective observational study", Epilepsia, 51, pp.251~256 (2010)
  50. Sutter R, "Mortality and recovery from refractory status epilepticus in the intensive care unit : a 7-year observational study", Epilepsia, 54, pp.502~511 (2013)
  51. Kowalski RG, "Third-line antiepileptic therapy and outcome in status epilepticus : the impact of vasopressor use and prolonged mechanical ventilation", Crit Care Med, 40, pp.2677~2684 (2012)
  52. Hocker SE, "Predictors of outcome in refractory status epilepticus", JAMA Neurol, 70, pp.72~77 (2013)
  53. Sutter R, "Anesthetic drugs in status epilepticus: risk or rescue? A 6-year cohort study", Neurology, 82, pp.656~664 (2014)
  54. Marchi NA, "Status epilepticus : impact of therapeutic coma on outcome", Crit Care Med, 43, pp.1003~1009 (2015)
  55. Fragen RJ, "Pharmacokinetics and pharmacodynamics of midazolam given via continuous intravenous infusion in intensive care units", Clin Ther, 19, pp.405~419 (1997)
  56. Fernandez A, "High-dose midazolam infusion for refractory status epilepticus", Neurology, 82, pp.359~365 (2014)
  57. Bailie GR, "Pharmacokinetics of propofol during and after long-term continuous infusion for maintenance of sedation in ICU patients", Br J Anaesth, 68, pp.486~491 (1992)
  58. Kotani Y, "The experimental and clinical pharmacology of propofol, an anesthetic agent with neuroprotective properties", CNS Neurosci Ther, 14, pp.95~106 (2008)
  59. Mirrakhimov AE, "Propofol infusion syndrome in adults : a clinical update", Crit Care Res Pract, 2015, pp.260385~ (2015)
  60. Ferlisi M, "The outcome of therapies in refractory and super-refractory convulsive status epilepticus and recommendations for therapy", Brain, 135, pp.2314~2328 (2012)
  61. Claassen J, "Treatment of refractory status epilepticus with pentobarbital, propofol, or midazolam : a systematic review", Epilepsia, 43, pp.146~153 (2002)
  62. Rossetti AO, "A randomized trial for the treatment of refractory status epilepticus", Neurocrit Care, 14, pp.4~10 (2011)
  63. Meierkord H, "EFNS guideline on the management of status epilepticus in adults", Eur J Neurol, 17, pp.348~355 (2010)
  64. Gomes D, "Consensus protocol for the treatment of super-refractory status epilepticus", Acta Med Port, 31, pp.598~605 (2018)
  65. Naylor DE, "Trafficking of GABAA receptors, loss of inhibition, and a mechanism for pharmacoresistance in status epilepticus", J Neurosci, 25, pp.7724~7733 (2005)
  66. Naylor DE, "Glutamate and GABA in the balance: convergent pathways sustain seizures during status epilepticus", Epilepsia, 51(Suppl 3), pp.106~109 (2010)
  67. Rosati A, "Efficacy and safety of ketamine in refractory status epilepticus in children", Neurology, 79, pp.2355~2358 (2012)
  68. Gaspard N, "Intravenous ketamine for the treatment of refractory status epilepticus : a retrospective multicenter study", Epilepsia, 54, pp.1498~1503 (2013)
  69. Rosati A, "Ketamine for refractory status epilepticus : a systematic review", CNS Drugs, 32, pp.997~1009 (2018)
  70. Zeiler FA, "Early use of the NMDA receptor antagonist ketamine in refractory and superrefractory status epilepticus", Crit Care Res Pract, 2015, pp.831260~ (2015)
  71. Fujikawa DG, "Status epilepticus: mechanism and management", pp.109~112 (2006), MIT Press
  72. Bauer G, "Nonconvulsive status epilepticus and coma", Epilepsia, 51, pp.177~190 (2010)
  73. Sutter R, "Nonconvulsive status epilepticus in adults-insights into the invisible", Nat Rev Neurol, 12, pp.281~293 (2016)
  74. Uysal U, "Intravenous anesthesia in treatment of nonconvulsive status epilepticus : characteristics and outcomes", Epilepsy Res, 116, pp.86~92 (2015)
  75. Amengual-Gual M, "Novel drugs and early polypharmacotherapy in status epilepticus", Seizure, 68, pp.79~88 (2019)
  76. Wasterlain CG, "Rational polytherapy in the treatment of acute seizures and status epilepticus", Epilepsia, 52, pp.70~71 (2011)

관련 논문AI추천

Treatments for Convulsive and Nonconvulsive Status Epilepticus in Adults: An Expert Opinion Survey in South Korea강경욱, 김근태, 김대영, 김동욱, 김재문, 노영주, 변정익, 서종근, 양광익, 이순태, 조용원대한신경과학회 · Journal of Clinical Neurology2021 · 제17권 제1호Status Epilepticus and Beyond: A Clinical Review of Status Epilepticus and an Update on Current Management Strategies in Super-refractory Status EpilepticusGene Sung, Roy Poblete대한중환자의학회 · Acute and Critical Care2017 · 제32권 제2호Refining General Principles of Antiepileptic Drug Treatments for Epilepsy강경욱, 김근태, 김대영, 김동욱, 노영주, 변정익, 서종근, 양광익, 이순태, 조용원대한신경과학회 · Journal of Clinical Neurology2020 · 제16권 제3호Prehospital Levetiracetam Use in Adults With Status Epilepticus: Results of a Multicenter RegistryEmanuel F. Bruno, Felix Kohle, Gereon R. Fink, Lothar Burghaus, Marie Madlener, Michael P. Malter, Volker Limmroth대한신경과학회 · Journal of Clinical Neurology2023 · 제19권 제4호Antiepileptic Drug Selection According to Seizure Type in Adult Patients with Epilepsy강경욱, 김근태, 김대영, 김동욱, 김혜윤, 노영주, 변정익, 서종근, 양광익, 이순태, 조용원대한신경과학회 · Journal of Clinical Neurology2020 · 제16권 제4호약물난치성 뇌전증 환자의 약물 치료 권고사항: 2021 대한신경과학회 진료지침 뇌전증 분과 소위원회구용서, 김대영, 김지영, 서종근, 손영민, 송홍기, 신동진, 정기영대한신경과학회 · 대한신경과학회지2021 · 제39권 제4호

이 간행물의 다른 논문 (25건)

Tinnitus Update류상효, 한병인, 김지수, 이호원pp. 1-10Treatments for Convulsive and Nonconvulsive Status Epilepticus in Adults: An Expert Opinion Survey in South Korea변정익, 노영주, 김동욱, 김근태, 김대영, 김재문, 강경욱, 서종근, 조용원, 이순태, 양광익pp. 20-25Clinical Characteristics and Treatment Outcomes of De Novo Nonconvulsive Status Epilepticus: A Retrospective Study이정주, 강규식, 이웅우, 박종무, 권오현, 김병건, 박경일pp. 26-32The Early Response to Dietary Therapy can Predict the Late Outcome in Children with Intractable Epilepsy장한나, 고태성, 염미선, 김민지, 임수영, 안현지pp. 33-40Decreased 18F-Fluorodeoxyglucose Uptake in Lumbar Vertebrae of Stroke Patients김정민, 석주원, 박광열, 이은성pp. 41-45
원문 보기